Bioequivalence Study of Chong Kun Dang Tamsulosin vs. Harnal-D in Healthy Volunteers

Phase 1, randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from time zero to the last measurable concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Mar 2019; status: completed.